What Does RAPT Therapeutics ($RAPT) Do? - Stock Outlook, Performance, Market Cap, Related Stocks, and Headquarters Overview
Allergy-treatment biotech. Ozureprubart IgE antibody therapeutic. Q3 2025 loss improvement, sufficient cash. GSK acquisition (January 2026).
Subscribe🏢 What kind of company is RAPT Therapeutics?
RAPT Therapeutics Inc (RAPT) is a biotechnology company specialized in treating immune-inflammatory diseases, with its lead product being ozureprubart, a half-life-extended monoclonal antibody currently in development. Ozureprubart is a therapeutic that binds to free IgE (immunoglobulin E), targeting food allergies (prestIgE Phase 2b) and chronic spontaneous urticaria (Phase 2/3), among other indications. The company is also developing a small-molecule program targeting G-protein-coupled receptors (GPCRs). It raised substantial capital through a 2025 public offering to strengthen its cash position. With the completion of GSK's acquisition in January 2026, the company has joined the portfolio of a major pharmaceutical company.
How does it make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Ozureprubart (IgE antibody) | Approximately 85% | Food allergy and urticaria therapeutic |
| GPCR program | Approximately 10% | CCR4 antagonist, small-molecule anti-inflammatory |
Q3 2025 total quarterly revenue was $0.0M, posting a year-over-year change of -. The Q3 2025 net loss improved compared with the year-earlier period. R&D spending decreased, with the focus on advancing clinical programs. The company raised substantial capital through a public offering to strengthen funding for clinical development and operations.
📐 Market cap and company size
Market capitalization stands at $1.6B, and the company employs 68 people people.
As a leading drug developer in the allergy and inflammatory disease market, the company holds strong clinical potential with ozureprubart. Phase 2 trials demonstrated efficacy and safety comparable to omalizumab, while Q8W/Q12W dosing offers improved convenience. Development plans span multiple indications, including food allergies (prestIgE Phase 2b) and chronic spontaneous urticaria (Phase 3 ongoing). The GSK acquisition brings global development capabilities and resources, accelerating commercialization.
📈 RAPT Therapeutics outlook and stock trends
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe allergy and inflammatory disease market is a structurally growing market driven by rising disease awareness, unmet medical demand, and lifestyle changes. Ozureprubart offers improved dosing convenience over omalizumab (Xolair) (Q8W/Q12W versus Q4W), presenting a meaningful market-share opportunity. However, competition with existing therapies, regulatory approval uncertainty, and FDA Hold risks on the GPCR program warrant caution. The completion of the GSK acquisition signals faster clinical development and strengthened regulatory support.
⚔️ Core strengths and risks
An innovative IgE antibody and high clinical potential are strengths, but regulatory risk and intensifying competition are key challenges.
💪 Core strengths
⚠️ Core risks
Competitors and related (beneficiary) stocks
Major competitors in the allergy therapeutics space include large pharmaceutical companies such as Regeneron (REGN, supplier of omalizumab/Xolair), Sanofi, and GSK. Smaller biotechs such as Gossamer Bio and Kiniksa Pharmaceuticals are also developing allergy therapeutics. RAPT's strengths lie in ozureprubart's dosing convenience and strong clinical profile.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | $810.32 | -2.1% | $83.4B | 20.0 | 2.6 | 14.04% | 0.49% |
| SNY | Sanofi ADR | $43.15 | -2.5% | $102.9B | 22.2 | 1.3 | 5.7% | 5.68% |
| GSK | GSK Plc ADR | $48.54 | -2.7% | $97.3B | 15.3 | 4.2 | 29.69% | 3.86% |
 GOSS | Gossamer Bio Inc | $0.18 | +2.6% | $87.9M | - | - | -783.37% | - |
 KNSA | Kiniksa Pharmaceuticals International Plc | $77.09 | -1.1% | $6.0B | 78.4 | 9.2 | 14.04% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | $269.12 | -2.2% | $648.6B | 31.2 | 7.6 | 25.74% | 2% |
| AMGN | AMGEN Inc | $393.17 | -10.1% | $212.6B | 24.4 | 18.2 | 91.47% | 2.57% |
| BIIB | Biogen Inc | $212.50 | -3.8% | $31.4B | 37.6 | 1.7 | 4.58% | - |
| VRTX | Vertex Pharmaceuticals Inc | $528.90 | -3.1% | $134.1B | 30.8 | 6.6 | 23.54% | - |
✅ Investor checkpoints
RAPT Therapeutics is advancing ozureprubart, an innovative allergy therapeutic. The Q3 2025 net-loss improvement and stronger cash position demonstrate progress in clinical development. The completion of the GSK acquisition (January 2026) means accelerated commercialization and strengthened regulatory support, with the Phase 3 progress being a near-term milestone.
| Checkpoint | What to verify | Current status |
|---|---|---|
| 💊 Ozureprubart clinical | prestIgE Phase 2b and CSU Phase 3 progress | Phase 3 enrollment and clinical data readouts |
| 📊 Clinical data | Safety/efficacy data in food allergy and urticaria trials | Superiority over omalizumab demonstrated |
| 🏥 GSK integration | Development plans and commercialization timelines under GSK | Degree of leveraging GSK's global capabilities |
Key concerns center on FDA regulatory uncertainty, market entry by omalizumab and emerging competing therapeutics, the continuation of the FDA Hold on the GPCR program, and the burden of commercialization costs. In particular, if Phase 3 results show unexpected safety signals, development could be halted.
RAPT Therapeutics has demonstrated high clinical potential as the developer of ozureprubart, an innovative allergy therapeutic. The Q3 2025 net-loss improvement and sufficient cash on hand, combined with the completion of the GSK acquisition (January 2026), signal advancing clinical progress and accelerated commercialization. Looking ahead, the outcome of Phase 3 is expected to be the key variable that will determine ozureprubart's market success and the company's value.
Check RAPT Therapeutics' real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free